Balanced news tone
News Sentiment
ELDN sentiment intelligence
Eledon Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
61 relevant articles
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-2.5% over one week, +7.8% over four weeks, trend active, and materially above fair value.
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
76/100 classification
One-week reaction
-2.5%
Price reacting lower
Trend fit
Trend active
7.8% over four weeks
Fair value
42.8%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
20
Neutral
37
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
StockStory
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 07:00
- Source
- StockStory
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
www.marketscreener.com
Direct company coverage
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index
Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell Microcap Value Benchmark Index, as well as the Russell Small Cap Comp Value Benchmark and Russell 3000 Value Benchmark Indices. This news follows several recent developments for the company, including
- Tone
- Negative 20/100
- Event
- Market update
- Published
- 29 Jun 2026 13:10
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark
Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell Small Cap Comp Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on immune-modulating therapies, with its lead product, tegoprubart, targeting CD40 Ligand. This news follow
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 29 Jun 2026 10:13
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark
Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell 2000 Value Benchmark Index. This news follows several other announcements detailing the company's removal from various Russell indices, including the Microcap Value, Small Cap Comp Value, 3000 Value, 3
- Tone
- Negative 32/100
- Event
- Market update
- Published
- 29 Jun 2026 00:11
- Source
- marketscreener.com
The Globe and Mail
Direct company coverage
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are showing bullish sentiment towards two healthcare companies, Definium Therapeutics (DFTX) and Eledon Pharmaceuticals (ELDN). LifeSci Capital maintained a Buy rating on Definium Therapeutics with a $63.00 price target, while also reaffirming a Buy rating on
- Tone
- Positive 85/100
- Event
- Analyst action
- Published
- 28 Jun 2026 14:39
- Source
- The Globe and Mail
TradingView
Direct company coverage
Price to sales forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN
This article provides financial information for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), specifically focusing on its Price to Sales (forward) metric. It appears to be a data point from TradingView, offering a snapshot of the company's valuation from a financial perspective.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 01:09
- Source
- TradingView
Moomoo
Direct company coverage
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8
LifeSci Capital has reiterated its Buy rating on Eledon Pharmaceuticals (ELDN.US), maintaining a target price of $8. This indicates the firm's continued confidence in the company's stock performance.
- Tone
- Positive 75/100
- Event
- Analyst action
- Published
- 27 Jun 2026 23:10
- Source
- Moomoo
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN
The article discusses the enterprise value to EBITDA forward for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN). It appears to be a truncated financial data page from TradingView, providing an overview of the company's financial metric without detailed analysis or figures. The conte
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 22:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN
This page displays financial information for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), specifically its Enterprise Value to EBIT forward. It indicates that the market was closed with no trades at the time of viewing. The content also features various navigation and information
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 12:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. – SWB:2TK
This article provides an analysis of the Enterprise Value to Revenue (EV/R) forward for Eledon Pharmaceuticals, Inc. (SWB:2TK). It presents the current value and changes in this financial metric for the company, indicating insights for potential investors or analysts.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 10:40
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN
This article displays the "Price to earnings forward" value for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) on TradingView. It provides a quick overview of this financial metric for the company. The page appears to be a financial data snippet from a larger platform rather than a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 02:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. – SWB:2TK
This article focuses on the enterprise value to EBIT forward for Eledon Pharmaceuticals, Inc. (SWB:2TK) on the Stuttgart Stock Exchange. It provides a financial overview and market data, indicating that the market is currently closed with no trades. The content highlights the sto
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 14:10
- Source
- TradingView
Investing.com
Direct company coverage
Natera’s Prospera test selected for Eledon kidney transplant trial
Natera's Prospera kidney transplant assessment test has been chosen for Eledon Pharmaceuticals' upcoming Phase 3 clinical trial of tegoprubart. This trial, set to begin in late 2026 and enrolling 600 kidney transplant recipients globally, will use Prospera as the sole donor-deriv
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 25 Jun 2026 14:41
- Source
- Investing.com
TradingView
Direct company coverage
ELDN Forecast — Price Target — Prediction for 2027
This article provides an overview of Eledon Pharmaceuticals, Inc. (ELDN) stock, including analyst price targets, historical performance, and financial data. It highlights the current stock price, recent changes, market capitalization, and upcoming earnings report. The analysis al
- Tone
- Positive 67/100
- Event
- Analyst action
- Published
- 25 Jun 2026 13:41
- Source
- TradingView
MT Newswires
Direct company coverage
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 12:05
- Source
- MT Newswires
Business Wire
Direct company coverage
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera and Eledon Pharmaceuticals have announced a strategic partnership to integrate Natera's Prospera kidney transplant assessment test into Eledon's upcoming Phase 3 clinical trial for tegoprubart, an investigational therapy aimed at preventing organ rejection. Prospera will s
- Tone
- Positive 70/100
- Event
- Regulatory and legal
- Published
- 25 Jun 2026 10:41
- Source
- Business Wire
Stock Titan
Direct company coverage
Eledon trial will use Natera’s Prospera test to track kidney rejection
Natera and Eledon Pharmaceuticals have announced a strategic partnership for Eledon's planned Phase 3 kidney transplant trial. Natera's Prospera test, which detects early signs of rejection and allograft injury, will be the exclusive donor-derived cell-free DNA (dd-cfDNA) monitor
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 25 Jun 2026 10:41
- Source
- Stock Titan
Moomoo
Direct company coverage
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10
Noble Financial has reiterated its Buy rating for Eledon Pharmaceuticals (ELDN.US) and maintained its price target at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 24 Jun 2026 08:41
- Source
- Moomoo
Seeking Alpha
Direct company coverage
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow (NASDAQ:ELDN) 2026-06-22
Eledon Pharmaceuticals, Inc. (ELDN) has released updated long-term data from its Phase 2 BESTOW clinical trial in kidney transplantation, which was presented in a slideshow. The trial's findings are significant for the company and its investors, highlighting ongoing developments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 02:41
- Source
- Seeking Alpha
Stock Titan
Direct company coverage
Eledon (NASDAQ: ELDN) holders approve share increase and board slate
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) stockholders approved increasing authorized common stock from 300 million to 450 million shares and re-elected three Class III directors (David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson) at their annual meeting on J
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:41
- Source
- Stock Titan
grafa.com
Direct company coverage
Eledon reports Phase 2 BESTOW kidney transplant data
Eledon Pharmaceuticals announced positive long-term Phase 2 extension data for tegoprubart in kidney transplant patients, showing higher kidney function compared to traditional tacrolimus regimens. The company's shares rose following the announcement, and they plan to use these r
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 22 Jun 2026 16:40
- Source
- grafa.com
www.marketscreener.com
Direct company coverage
Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation
Eledon Pharmaceuticals announced positive long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplant patients. Results showed tegoprubart-treated patients maintained significantly higher mean eGFR and had fewer adverse events and no biopsy-proven
- Tone
- Positive 95/100
- Event
- Earnings
- Published
- 22 Jun 2026 13:40
- Source
- www.marketscreener.com
Investing.com
Direct company coverage
Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data
Cantor Fitzgerald has reiterated an Overweight rating on Eledon Pharmaceuticals (NASDAQ:ELDN) following positive Phase 2 study data for its kidney transplant drug candidate, tegoprubart. The drug showed stable to improved kidney function compared to standard-of-care tacrolimus. E
- Tone
- Positive 74/100
- Event
- Analyst action
- Published
- 22 Jun 2026 12:40
- Source
- Investing.com
www.marketscreener.com
Direct company coverage
Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus
Eledon Pharmaceuticals announced that mid-stage data for its drug tegoprubart in kidney transplantation showed higher kidney function and improved outcomes compared to tacrolimus. The company's lead investigational product, tegoprubart, is an IgG1, anti-CD40L antibody aimed at im
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 22 Jun 2026 12:40
- Source
- www.marketscreener.com
GlobeNewswire
Direct company coverage
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 22 Jun 2026 11:00
- Source
- GlobeNewswire
Investing.com
Direct company coverage
Eledon reports kidney function benefit for tegoprubart at 18 months
Eledon Pharmaceuticals Inc. presented positive long-term data from its Phase 2 BESTOW clinical trial, showing that tegoprubart-treated kidney transplant patients had significantly better kidney function at 18 months compared to those treated with tacrolimus. The company's shares
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 22 Jun 2026 11:40
- Source
- Investing.com
GlobeNewswire
Direct company coverage
Eledon Presents Long-Term Extension Phase 2 BESTOW Results
Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplant patients, presented at the American Transplant Congress. The data showed sustained higher kidney function, no biopsy-proven acute rejection events aft
- Tone
- Positive 74/100
- Event
- Earnings
- Published
- 22 Jun 2026 10:40
- Source
- GlobeNewswire
Investing.com
Direct company coverage
Leerink raises Eledon Pharmaceuticals price target on trial data
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 22 Jun 2026 07:00
- Source
- Investing.com
RTTNews
Direct company coverage
Eledon Pharma To Present At The American Transplant Congress
Eledon Pharmaceuticals Inc. (ELDN) is scheduled to present at the American Transplant Congress (ATC) from June 20-24, 2026, in Boston. The company will host a conference call on June 22, 2026, to discuss updated data from the Phase 2 BESTOW clinical trial and new long-term data f
- Tone
- Positive 68/100
- Event
- Market update
- Published
- 18 Jun 2026 12:09
- Source
- RTTNews